AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

Investors' focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it ...

We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

AbbVie's immunology franchise remains a key driver of growth, with Skyrizi and Rinvoq continuing to gain market share and exceed analyst expectations. These two drugs are crucial to the company's ...